Notably, PTEN deletion is frequently observed in primary prostate tumors with high levels of intratumor heterogeneity [82], and the heterogeneity of PTEN loss within a primary prostate tumor has also been shown to influence clinical outcome [83]. The gene discussed is PTEN; the disease is prostate neoplasm.